1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Niagen Bioscience Inc

Niagen Bioscience Inc

NAGE
Niagen Bioscience IncUS flagNASDAQ Capital Market
2.50
USD
- -
- -
197.82MMarket Cap
Niagen Bioscience Inc
NAGE
(NASDAQ Capital Market)

Recent

price

2.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.47
0.36
0.39
0.3
0.43
0.5
0.58
0.48
0.57
0.81
0.97
1
1.03
1.11
1.31
1.63
1.62
Revenue per Share
-0.13
-0.35
-0.39
-0.13
-0.15
-0.08
-0.08
-0.26
-0.61
-0.56
-0.33
-0.4
-0.24
-0.07
0.11
0.22
0.2
Basic EPS, GAAP
-0.18
-0.19
-0.34
-0.12
-0.08
-0.08
-0.12
-0.25
-0.41
-0.37
-0.18
-0.37
-0.22
0.09
0.16
0.17
0.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.24
0.11
0.13
0.16
0.11
0.15
0.27
0.98
0.49
0.34
0.27
0.47
0.38
0.38
0.6
0.96
1.05
Book Value per Share
0.23
0.1
0.13
0.16
0.11
0.14
0.25
0.95
0.47
0.32
0.25
0.45
0.38
0.37
0.59
0.89
0.98
Tangible Book Value per Share
16
23
30
33
35
36
37
45
55
57
61
67
70
75
76
79
79
Basic Weighted Avg Shares
8
8
12
10
15
18
22
21
32
46
59
67
72
84
100
129
129
Sales/Revenue/Turnover
-26.66
-96.94
-100.22
-42.73
-33.86
-11.55
-13.41
-77.25
-105.12
-67.62
-33.5
-40.14
-25.85
-6.7
7.76
11.05
6.67
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
1
2
2
2
2
2
1
1
2
Depreciation Expense
-2
-8
-12
-4
-5
-3
-3
-11
-33
-32
-20
-27
-17
-5
9
17
16
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.44
4.45
6.09
Effective Tax Rate (%)
-27.12
-97.32
-100.45
-43.5
-35.19
-15.49
-13.52
-53.67
-105.57
-69.45
-33.62
-40.22
-22.96
-5.91
8.58
13.43
12.39
Profit Margin (%)
4
2
3
3
5
7
7
49
22
18
16
31
29
29
46
77
83
Working Capital
- -
- -
- -
- -
2
4
- -
- -
- -
1
1
4
4
3
2
2
1
LT Debt
5
3
4
6
4
5
10
54
27
20
16
32
29
28
46
77
83
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
18.58
21.37
10.64
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
21.25
27.14
20.99
Return on Capital (%)
-68.58
-210.6
-355.85
-91.51
-111.51
-59.77
-38.4
-35.66
-82.25
-135.01
-108.09
-112.68
-54.77
-17.29
22.94
28.35
21.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
80
79
79
Market Capitalization
507
350
252

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
97
105
98
Cash, Cash Equivalents & STI
65
66
67
Accounts Receivable, Net
10
13
9
Inventories
20
24
21
Total Current Liabilities
20
23
15
Payables & Accruals
19
21
13
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
64.57%
42.16%
66.04%
Free Cash Flow
28.26%
5.68%
10.6%
Net Income, GAAP
20.26%
-48.58%
103.3%
Sales/Revenue/Turnover
22.83%
17.15%
29.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22
23
26
29
100
2025
30
31
34
34
129
2026
31
30
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
- -
0.02
0.09
0.11
2025
0.07
0.05
0.06
0.05
0.22
2026
0.08
0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Alpha Cognition Inc. (ACOGF)
Bright Minds Biosciences Inc. (DRUG)
Clearmind Medicine Inc. (CMND.CN)
Baudax Bio, Inc. (BXRX)
Pharma Equity Group A/S (PEG.CO)
Clal Biotechnology Industries Ltd. (CBI.TA)
Business
Niagen Bioscience Inc (Ticker: NAGE) develops and commercializes innovative bioscience products focused on cellular health and energy metabolism, primarily through nicotinamide riboside (NR) branded as Niagen, a clinically validated precursor to NAD+ that supports mitochondrial function and healthy aging. The company offers Niagen in various formulations, including bulk ingredients for dietary supplements, branded consumer products such as capsules and powders, and custom formulations for sports nutrition and longevity markets; it also provides research-grade Niagen for clinical studies and contract manufacturing services for NAD+-boosting nutraceuticals. Headquartered in Reno, Nevada, Niagen Bioscience was founded in 2013 as part of the ChromaDex ecosystem before spinning out as an independent entity, with operations spanning North America, Europe, and Asia-Pacific targeting supplement manufacturers, healthcare professionals, and direct-to-consumer channels in the nutraceutical and wellness industries. In late 2024, the company completed a significant uplisting to NASDAQ under ticker NAGE following a reverse merger, enhancing its capital access for global expansion; it announced a strategic partnership with a leading Asian distributor to accelerate Niagen adoption in the high-growth longevity market and launched Niagen Pro, a professional-grade line for practitioners in 2025. Niagen Bioscience continues to invest in R&D for next-generation NAD+ precursors amid rising demand for anti-aging interventions, with no major subsidiaries but key alliances with contract manufacturers worldwide.

Company News

Company News APIChatGPT

  • businesswire.com

    Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product

  • gurufocus.com

    Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

  • businesswire.com

    Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

  • defenseworld.net

    Niagen Bioscience (NASDAQ:NAGE) and Beauty Health (NASDAQ:SKIN) Head to Head Review

  • businesswire.com

    Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)

  • businesswire.com

    Niagen Bioscience to Present at LD Micro 20th Annual Main Event

  • businesswire.com

    Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.

  • businesswire.com

    Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial

  • defenseworld.net

    Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Recommendation of “Buy” by Analysts

  • businesswire.com

    Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes

  • businesswire.com

    Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

  • businesswire.com

    Niagen Bioscience to Present at Canaccord Genuity's Well Summit

  • businesswire.com

    Niagen Bioscience to Present at Longevity Investors Conference

  • gurufocus.com

    Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

  • businesswire.com

    Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

  • gurufocus.com

    Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club

  • businesswire.com

    Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club

  • businesswire.com

    Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

  • businesswire.com

    Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

  • seekingalpha.com

    Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript